Neoantigen-Based Therapeutic Targeting of Head and Neck Cancers (R01)
ArchivedNational Institutes of Health
Description
The purpose of this Funding Opportunity Announcement (FOA) is to support basic and preclinical research aimed at developing novel immunotherapeutic targets for head and neck cancers (HNC), including salivary gland cancers. Research supported by this FOA will identify human HNC-specific neoantigens, and will test the utility of these neoantigens as targets for eliciting anti-tumor immune responses in affected patient populations.
Who can apply
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities / Indian housing authorities
- Native American tribal organizations (other than Federally recognized)
- Nonprofits with 501(c)(3) status (other than higher education)
- Nonprofits without 501(c)(3) status (other than higher education)
- Private institutions of higher education
- For-profit organizations other than small businesses
- Small businesses
- Others
Contact
NIH OER Webmaster<br/>FBOWebmaster@OD.NIH.GOV<br/>
FBOWebmaster@OD.NIH.GOV
- PostedFeb 27, 2017
- ClosesJun 19, 2017
- Award ceiling$350,000
- Program funding$3,000,000
- CFDA93.121
Pro insight
Edit and export this grant’s proposal template, plus deadline reminders, similar-grant suggestions, and funder history — all available with Pro.
Unlock with Pro